Peptide ligands in antibacterial drug discovery: use as inhibitors in target validation and target-based screening

Bibliography

• WHO: WHO report on Infectious Diseases: Removing Obstacles to Healthy Development. Geneva, Switzerland (1999).
   Google Scholar
• GRAYSON ML, ELIOPOULOS GM: Antimicrobial resistance in the intensive care unit. Sem. Resp. Infect. (1990) 5:204–214.
   PubMedGoogle Scholar
• FRIDKIN SK: Increasing prevalence of antimicrobial resistance in intensive care units. Crit. Care Med. (2001) 29:64–68.
   PubMed Web of Science ®Google Scholar
• GOLD HS, MOELLERING RC JR: Antimicrobial-drug resistance. N Engl. J. Med. (1996) 335:1445–1453.
   PubMed Web of Science ®Google Scholar
• NEU HC: The crisis in antibiotic resistance. Science (1992) 257:1064–1073.
   PubMed Web of Science ®Google Scholar
• PINNER RW, TEUTSCH SM,SIMONSEN L et al.: Trends in infectiousdiseases mortality in the United States. JA/VIA (1996) 275:189–193.
   Google Scholar
• CASSELL GH: Emergent antibiotic resistance: health risks and economic impact.FEMS Immunol. Med. Micro. (1997) 18:271–274.
   PubMedGoogle Scholar
• KADAM, S: Mechanism-based screens inthe discovery of chemotherapeutic antibacterials. Biotechniques (1994) 26:247–266.
   Google Scholar
• CHOPRA I, HODGSON J, METCALF B,POSTE G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicr. Agents Chemo. (1997) 41:497–503.
   PubMed Web of Science ®Google Scholar
• ELIOPOULOS GM, ELIOPOULOS CT: Ciprofloxacin in combination with other antimicrobials. Am. J. Med. (1989) 87:17S–22S.
   Google Scholar
• CASSELL GH, MEKALANOS JJ: Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA (2001) 285:601–605.
   PubMed Web of Science ®Google Scholar
• ELIOPOULOS GM,MOELLERING RC JR: Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect. Dis. (1982) 4:282–293.
   PubMedGoogle Scholar
• LEVY SB: The challenge of antibiotic resistance. Sci. Amer (1998) 278:46–53.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, GAYNES RP: Antimicrobial resistance in intensive care units. Clin. Chest Med. (1999) 20:303–316.
   PubMed Web of Science ®Google Scholar
• DAVIES J: Origins and evolution of bacterial resistance. Microbiologica (1996) 12.9–16.
   Google Scholar
• WALSH C: Molecular mechanisms that confer antibacterial drug resistance. Nature (2000) 406:775–781.
   PubMed Web of Science ®Google Scholar
• ••Excellent review describing the targets forthe main classes of known antibiotics and a detailed account of the bacterial strategies and mechanisms that lead to resistance. Also provides some guidelines for extending the lifetimes of antibacterial drugs.
   Google Scholar
• KOONIN EV, MUSHEGIAN AR, RUDD KE: Sequencing and analysis of bacterial genomes. Curt: Biol. (1996) 6:404–416.
   PubMedGoogle Scholar
• TANG CM, MOXON ER: The impact of microbial genomics on antimicrobial drugdevelopment. Ann. Rev Gen. Human Genet. (2001) 2:259-269.Good review of the approaches to exploit genomic database information including bioinformatics, transcriptional analysis and the criteria involved in target identification and selection.
   Google Scholar
• ALM RA, TRUST TJ: Analysis of the genetic diversity of Helicobacter pylori the tale of two genomes. Ma Med. (1999) 77:834–846.
   PubMedGoogle Scholar
• DUNN BE, COHEN H, BLASER MJ: Helicobacter pykri. Clin. Micro. Rev (1997) 10:720–741.
   PubMed Web of Science ®Google Scholar
• KARP PD: Metabolic databases. Tien. Biochem. Sci. (1998) 23:114–116.
   PubMedGoogle Scholar
• ALTINCICEK B, KOLLAS AK, SANDERBRAND S et al: GcpE is involved in the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coil. J. Bac. (2001) 183:2411–2416.
   PubMedGoogle Scholar
• MANILOFF J: The minimal cell genome:'on being the right size'. Proc. Nati Acad. Sci. USA (1996) 93:10004–10006.
   PubMedGoogle Scholar
• MUSHEGIAN AR, KOONIN EV: A minimal gene set for cellular life derived by comparison of complete bacterial genomes. Proc. Nati Acad. Sci. USA (1996) 93:10268–10273.
   PubMed Web of Science ®Google Scholar
• FINLAY, BB, FALKOW S: Common themes in microbial pathogenicity. Micro. Rev (1989) 53:210–230.
   PubMedGoogle Scholar
• •Excellent review of the genetic strategies used by bacteria during the infection process. Contains a detailed discussion on the production of toxins, adherence and invasion factors. The mechanisms of survival of intracellular pathogens are also described.
   Google Scholar
• GROISMAN EA, H OCHMAN H: Pathogenicity islands: bacterial evolution in quantum leaps. Cell (1996) 87:791–794.
   PubMed Web of Science ®Google Scholar
• STRAUSS EJ, FALKOW S: Microbial pathogenesis: genomics and beyond. Science (1997) 276:707–712.
   PubMed Web of Science ®Google Scholar
• •Review and perspective on the use of genomic information in combination with techniques, such as WET, STM and DFI to gain a thorough understanding of bacterial pathogenesis, and to possibly access novel drug targets.
   Google Scholar
• ARIGONI F, TALABOT F,PEITSCH M et al: A genome-based approach for the identification of essential bacterial genes. Nat. Biotech. (1998) 16:851–856.
   PubMed Web of Science ®Google Scholar
• •Provides a good example of how to identify potential drug targets using a genomic approach.
   Google Scholar
• HINTON JC: The Escherichia coil genomesequence: the end of an era or the start of the FUN? Ma Micro. (1997) 26:417–422.
   Google Scholar
• •Explanation of the pivotal role of E co/las a model system for studying bacterial gene function. Examination of why the function of so many genes in this well studied organism is still not understood.
   Google Scholar
• BLATTNER FR, PLUNKETT G 3RD, BLOCH CA et al.: The complete genome sequence of Escherichia coil K-12. Science (1997) 277:1453–1474.
   Google Scholar
• LINK AJ, PHILLIPS D, CHURCH GM: Methods for generating precise deletions and insertions in the genome of wild-type Escherichia colt. application to open reading frame characterization. I Bac. (1997) 179:6228–6237.
   PubMed Web of Science ®Google Scholar
• VAGNER V, DERVYN E, EHRLICH SD: A vector for systematic gene inactivation in Bacillus subtilis. Microbiology (1998) 144:3097–3104.
   PubMedGoogle Scholar
• SCHMID MB, KAPUR N, ISAACSON DR, LINDROOS P, SHARPE C: Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium. Genetics (1989) 123:625–633.
   PubMed Web of Science ®Google Scholar
• INOUYE M: Antisense RNA: its functions and applications in gene regulation-a review. Gene (1988) 72:25–34.
   PubMedGoogle Scholar
• AKERLEY BJ, RUBIN EJ,CAMILLI A et al.: Systematic identification of essential genes by in vitro mariner mutagenesis. Proc. Nati Acad. Sci. USA (1998) 95:8927–8932.
   Google Scholar
• JUDSON N, MEKALANOS JJ: Transposon-based approaches to identify essential bacterial genes. Tien. Micro. (2000) 8:521–526.
   PubMed Web of Science ®Google Scholar
• HUTCHISON CA, PETERSON SN, GILL SR et al.: Global transposon mutagenesis and a minimal Mycoplasma genome. Science (1999) 286:2165–2169.
   PubMed Web of Science ®Google Scholar
• CALIA KE, WALDOR MK, CALDERWOOD SB: Use of representational difference analysis to identify genomic differences between pathogenic strains of Vibrio cholerae. Infect. Immun. (1998) 66:849–852.
   PubMedGoogle Scholar
• TO KY: Identification of differential geneexpression by high throughput analysis.Combin. Chem. High Through. Screen.(2000) 3:235–241.
   PubMedGoogle Scholar
• VALDIVIA RH, FALKOW S: Bacterial genetics by flow cytometry: rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction. Ma Micro. (1996) 22:367–378.
   Google Scholar
• LOWE AM, BEATTIE DT, DERESIEWICZ RL: Identification of novel staphylococcal virulence genes by in vivo expression technology. Ma Micro. (1998) 27:967–976.
   Google Scholar
• MEI JM, NOURBAKHSH F, FORD CW, HOLDEN DW: Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Ma Micro. (1997) 26:399–407.
   Google Scholar
• DESNOTTES JF: New targets and strategies for the development of antibacterial agents. Trends Biotech. (1996) 14:134–140.
   PubMed Web of Science ®Google Scholar
• TALLY FP, TAO J, WENDLER PA et al.:Method for identifying validated target and assay combinations for drug development. (1999) W09935494.
   Google Scholar
• BLONDELLE SE, E PEREZ-PAYA E, HOUGHTEN RA: Synthetic combinatorial libraries: novel discovery strategy for identification of antimicrobial agents. Antimitc Agents Chemo. (1996) 40:1067–1071.
   PubMed Web of Science ®Google Scholar
• •Concise review of the utility of synthetic combinatorial libraries in the discovery of antibacterial drugs. Several examples of novel peptides and peptidomimetic compounds with antibacterial activity are discussed.
   Google Scholar
• OSTRESH JM, BLONDELLE SE, DORNER B, HOUGHTEN RA: Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. Meth. Enz. (1996) 267:220–234.
   PubMed Web of Science ®Google Scholar
• SCHAFFITZEL C, HANES J, JERMUTUS L, PLUCKTHUN A: Ribosome display: an in vitro method for selection and evolution of antibodies from libraries.j Immun. Meth. (1999) 231:119–135.
   PubMed Web of Science ®Google Scholar
• CWIRLA SE, PETERS EA, BARRETT RW, DOWER WJ: Peptides on phage: a vast library of peptides for identifying ligands. Proc. Nati Acad. Sci. USA (1990) 87:6378–6382.
   PubMed Web of Science ®Google Scholar
• LU Z, TRIPP BC, MCCOY JM: Displaying libraries of conformationally constrained peptides on the surface of Escherichia coil as flagellin fusions. Meth. Ma Biol. (1998) 87:265–280.
   PubMedGoogle Scholar
• SMITH GP, SCOTT JK: Libraries of peptides and proteins displayed onfilamentous phage. Meth. Enz. (1993) 217:228–257.
   PubMed Web of Science ®Google Scholar
• HYDE-DERUYSCHER R, PAIGE LA, CHRISTENSEN DJ et al.: Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. Chem. Biol. (2000) 7:17–25.
   PubMedGoogle Scholar
• •Provides several comprehensive examples of the characteristics of specific inhibitory peptides (identified through phage display) to a broad range of enzyme classes.
   Google Scholar
• LUTZ RH, JARD BU: Independent and tight regulation of transcriptional units in Escherichia colivia the LacR/O, the TetR/0 and AraC/I142 regulatory elements. Nuc. Acids Res. (1997) 25:1203–1210.
   PubMed Web of Science ®Google Scholar
• CHAFFIN DO, RUBENS CE: Blue/white screening of recombinant plasmids in Gram-positive bacteria by interruption of alkaline phosphatase gene (phoZ) expression. Gene (1998) 219:91–99.
   PubMedGoogle Scholar
• TALLY FP, TAO J, SHEN X et al.: Regulable gene expression in Gram-positive bacteria. (1999) W09953079.
   Google Scholar
• SANCHEZ-PESCADOR R, BROWN JT, ROBERTS M, URDEA MS: Homology of the TetM with translational elongation factors: implications for potential modes of tetM-conferred tetracycline resistance. Nuc. Acids Res. (1988) 16:12–18.
   Google Scholar
• TAO J, WENDLER P,CONNELLY G et al.: Drug target validation: lethal infection blocked by inducible peptide. Proc. Natl Acad. Sci. USA (2000) 97:783–786.
   Google Scholar
• ••First example of IVET by employing asmall peptide expressed intracellularly in bacteria.
   Google Scholar
• OLIVA B, GORDON G, MCNICHOLAS P, ELLESTAD G, CHOPRA I: Evidence that tetracycline analogs whose primary target is not the bacterial ribosome cause lysis of Escherichia colt. Antimicr. Agents Chemo. (1992) 36:913–919.
   PubMedGoogle Scholar
• RASMUSSEN B, NOLLER HF, DAUBRESSE G et al.: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicr. Agents Chemo. (1991) 35:2306–2311.
   PubMed Web of Science ®Google Scholar
• BLUM JH, DOVE SL,HOCHS CHILD A et al.: Isolation of peptide aptamers that inhibit intracellular processes. Proc. Nati Acad. Sci. USA (2000) 97:2241–2246.
   Google Scholar
• •Describes a potentially useful method to identify novel drug targets using peptide aptarners.
   Google Scholar
• TAO J, ADAMS J, CHAPPLE J et al: Application of VITATM technology to antibacterial drug discovery. 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (2001)Paper 2134.
   Google Scholar
• IVANOV I, SCHAAB C,PLANITZER S et al.: DNA microarray technology and antimicrobial drug discovery. Pharmacogenomics (2000) 1:169–178.
   Google Scholar
• NASIR MS, JOLLEY ME: Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Combin. Chem. High Through. Screen. (1999) 2:177–190.
   PubMed Web of Science ®Google Scholar
• •Good discussion on the theory, principles and limitations of FP with illustrative examples of its utility in binding assays, enzymatic reactions and in diagnostics.
   Google Scholar
• DICKSON EF, POLLAK A, DIAMANDIS EP: Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. Pharm. Therap. (1995) 66:207–235.
   PubMed Web of Science ®Google Scholar
• MILLAR DP: Time-resolved fluorescence spectroscopy. Carr. Opin. Struc. Biol. (1996) 6:637–642.
   PubMedGoogle Scholar
• HA T: Single-molecule fluorescence resonance energy transfer. Methods (Duluth) (2001) 25:78–86.
   PubMedGoogle Scholar
• NUMANN R, NEGULESCU PA: High-throughput screening strategies for cardiac ion channels. Trends Cardiovas. Med. (2001) 11:54–59.
   PubMedGoogle Scholar
• DENIZ AA, LAURENCE TA, DAHAN M et al.: Ratiometric single-molecule studies of freely diffusing biomolecules. Ann. Rev. Phys. Chem. (2001) 52:233–253.
   PubMedGoogle Scholar
• SCHMIDT T, SCHUTZ GJ, BAUMGARTNER W, GRUBER HJ, SCHINDLER H: Imaging of single molecule diffusion. Proc. Natl Acad. Sci. USA (1996) 93:2926–2929.
   PubMed Web of Science ®Google Scholar
• WOODBURY CP JR, VENTON DL: Methods of screening combinatorial libraries using immobilized or restrained receptors. I Chrom. Biomed. Sci. Applic. (1999) 725:113–137.
   PubMedGoogle Scholar
• DELAPORTE E, SLAUGHTER DE, EGAN MA et al.: The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol Screen. (2001) 6:225–231.
   PubMed Web of Science ®Google Scholar
• WEINBERGER SR, MORRIS TS, PAWLAK M: Recent trends in protein biochip technology. Pharmacogenomics (2000) 1:395–416.
   PubMedGoogle Scholar
• FARBER GK: New approaches to rationaldrug design. Pharm. Therap. (1999) 84:327–332.
   PubMedGoogle Scholar
• TAO J, SCHIMMEL P: Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives. Expert Opin. Investig. Drugs (2000) 9:1767–1775.
   PubMed Web of Science ®Google Scholar
• •In depth discussion of amino acyl-tRNA synthetases as antibacterial drug discovery targets.
   Google Scholar
• www.ncbi.nih.gov The National Centre for Biotechnology Information.
   Google Scholar